Abstract
Mazaticol, 6,6,9-trimethyl-9-azabicyclo[3,3,1]non-3β-yl-α,α-di-(2-thienyl) glycolate hydrochloride monohydrate, was developed by Tanabe Seiyaku Co. LTD. in1970s and started selling in 1978 in Japan. This agent has an anticholinergic activity in the central nervous system as the same degree of well-known anticholinergic medicine, trihexyphenidyl. Mazaticol and other anticholinergic agents are considered to block the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol has an affinity to M1 and M2 muscarinic acetylcholine receptor and had less peripheral activity compared to other anticholinergic agents. In the animal experiments, mazaticol exhibited inhibitory effects on dopamine uptake in the striatal nerve terminal. As for clinical indication, mazaticol is applied mainly to a psychotropic drug-induced parkinsonian syndrome. Many clinical evaluations showed efficacy of mazaticol is almost as same as the other anticholinergic agents. But mazaticol showed the improvement of symptoms for the cases in which other drugs had no effects. However, current clinical studies on mazaticol are not enough, especially for the idiopathic parkinsonian disease.
References
Fujimura K. Pakinson syoukougun ni taisuru pentona to sinmetoreru tono moukenhou ni yoru yakkou hikaku. J New Rem Clin. 1976;25(11):1917–20.
Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Grinberg A, Sheng H, Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96(4):1692–7.
Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440–7.
Katayama S, Ishizaki F, Yamamura Y, Khoriyama T, Kito S. Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain. Res Commun Chem Pathol Pharmacol. 1990;69:261–70.
Kawai Y, Noguchi M, Noguchi Y. Chronic toxicity study of an antiparkinsonian agent, 6,6,9-trimethyl-9-azabicyclo 3,3,1non-3β-yl α,α-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501) in rats. Pharmacometrics. 1974;9:1305–10.
Kosaka K. The beneficial effect of PG-501 on parkinsonism. Rinsho yakuri/Jpn J Clin Pharmacol Ther. 1971;2(3):230–5.
Meshi T, Nakamura S, Sato Y. Metabolic fate of 6, 6, 9-trimethyl-9-ayabicyclo[3, 3, 1]non-3β-yl α, α-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501). Chem Pharm Bull. 1972;8:1687–98.
Nakajima H, Matsuda Y. Yakuzaise pa-kinson syoukougun ni taisuru ensan mazatiko-ru (pentona®) no tiryou keiken. Clin Rep. 1986;20(2):1325–33.
Nose T, Kojima M, Isida R, Shintomi K, Kowa Y. Pharmacological properties of 6, 6, 9-trimethyl-9-ayabicyclo[3, 3, 1]non-3β-ylα, α-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent. Folia Pharmacol Japan. 1971;67:387–405.
Otsuka M, Nakamura S, Sato Y. Absorption, distribution and excretion of 14C-labelled 6, 6, 9-trimethyl-9-ayabicyclo[3, 3, 1]non-3β-ylα, α-di(2-thienyl) Glycolate hydrochloride monohydrate (PG-501). Yakugaku Zasshi (in Japanese). 1972;8:986–96.
Pharmaceutical products interview form in Japan. 2015. https://medical.mt-pharma.co.jp/di/file/if/f_pnt.pdf. Accessed 29 Aug 2017.
Saito M, Kita S, Kagono Y, Suitsu N, Honda Y. Computerized EEG study on drug-induced extrapyramidalism in schizophrenic patients. Electroencephalogr Clin Neurophysiol Suppl. 1982;36:524–37.
Suitsu N. A computer-assisted EEG study on psychotropic properties of antiparkinsonian drugs. Seishin Shinkeigaku Zasshi (in Japanese). 1992;94(3):238–62.
Takesada, Sakai T, Tutsumi S, Isoda K, Kondo H, Hujimura K, Iwatani N, Yamauchi I, Kato N. Pa-kinson syoukougun ni taisuru Mazaticol・HCl oyobi Amantidine・HCl no koukahikaku. Jpn J Clin Exp Med (in Japanese). 1977;54(5):1655–67.
Tanaka R, Ogata M, Honda O, Kinokuni U, Okamoto Y, Yagu S, Sakaoka U, Sanada H, Teraoka M, Kuji K. Effects of PG-501 on Parapyramidal system syndrome induced by Psychotropics. Med Consult New Remedies. 1972;9(3):641–6.
Yagi G, Yauchi N, Tokizawa T, Tashiro I, Takeda A, Sakurai S, Kobayashi T, Itou A. Yakubutusei suitaigairo syoujyou ni taisuru mazaticol hydrochloride, Trihexyphenidyl oyobi promethazine no koukahikaku – double-blind cross-over Mehtod no niyoru kentou. Jpn J Clin Psychiatry (in Japanese). 1973;2(11):1311–38.
Yamaguchi K, Ishihara H, Ariyuki F, Noguchi Y, Kowa Y. Teratological study of 6,6,9-Trimethyl-9-azabicyclo (3,3,1) non-3β-yl α,α-di-(2-thienyl) glycolate hydrochloride monohydrate (PG-501). Pharmacometrics. 1974;8(8):1213–8.
Yukawa E, Hokazono T, Yukawa M, Ichimaru R, Maki T, Matsunaga K, Ohdo S, Anai M, Higuchi S, Goto Y. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. Clin Pharmacokinet. 2002;41(2):153–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Niimi, Y., Mutoh, T. (2020). Mazaticol for Treating Parkinson. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_362-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_362-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine